[HTML][HTML] Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
E Goto, S Horinaka, T Ishimitsu, T Kato - … metabolism and pharmacokinetics, 2020 - Elsevier
… The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be inferred from their
… -state pharmacokinetics (PK) of different FXa inhibitors have not been compared in clinically. …
… -state pharmacokinetics (PK) of different FXa inhibitors have not been compared in clinically. …
[引用][C] Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
S Horinaka
Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination
J Mendell, RJ Noveck, M Shi - Journal of cardiovascular …, 2022 - journals.lww.com
… are currently widely used in clinical practice for rate control, albeit … factor Xa inhibitor: in vitro
and in vivo pharmacologic profiles. … of the novel factor Xa inhibitor edoxaban compared with …
and in vivo pharmacologic profiles. … of the novel factor Xa inhibitor edoxaban compared with …
Factor Xa inhibitory profile of apixaban, betrixaban, edoxaban, and rivaroxaban does not fully reflect their biologic spectrum
F Siddiqui, D Hoppensteadt, W Jeske… - Clinical and Applied …, 2019 - journals.sagepub.com
… Moreover, the pharmacokinetic and pharmacodynamic profiles … a comparison of the ACT
results with the different factor Xa … clinical setting to generate data on each of the individual anti-…
results with the different factor Xa … clinical setting to generate data on each of the individual anti-…
Microdosed cocktail of three oral factor Xa inhibitors to evaluate drug–drug interactions with potential perpetrator drugs
G Mikus, KI Foerster, M Schaumaeker… - … Pharmacokinetics, 2019 - Springer
… The microdosed FXaI cocktail showed similar pharmacokinetic parameters compared with
… The sensitivity of the analytical assay resulted in full pharmacokinetic profiles for all three …
… The sensitivity of the analytical assay resulted in full pharmacokinetic profiles for all three …
[HTML][HTML] Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco, SV Konstantinides - … Practice in Thrombosis and …, 2021 - Elsevier
… after an index episode of VTE in clinical practice. The direct oral anticoagulants (DOACs) …
safer profile compared to VKAs, mostly thanks to their (more) predictable pharmacokinetics …
safer profile compared to VKAs, mostly thanks to their (more) predictable pharmacokinetics …
Comparison of low-versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor–associated bleeding: a retrospective study
… Direct oral anticoagulant drugs offer several advantages compared to warfarin, including
rapid onset of action and elimination, predictable pharmacokinetics, improved safety profile, …
rapid onset of action and elimination, predictable pharmacokinetics, improved safety profile, …
Pharmacology and clinical development of factor XI inhibitors
A Greco, C Laudani, M Spagnolo, F Agnello, DC Faro… - Circulation, 2023 - Am Heart Assoc
… FXI inhibitors in clinical practice and to clarify which FXI inhibitor … and pharmacokinetic
characteristics of FXI inhibitors … asundexian will be compared to the factor Xa inhibitor apixaban for …
characteristics of FXI inhibitors … asundexian will be compared to the factor Xa inhibitor apixaban for …
[HTML][HTML] Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation
G Lu, J Lin, K Bui, JT Curnutte, PB Conley - … and Practice in Thrombosis and …, 2020 - Elsevier
… Direct oral factor Xa (FXa) inhibitors, such as apixaban and rivaroxaban, are used for the …
reversal of rivaroxaban (250 ng/mL) inhibition assessed by the TF‐TG profiles compared to …
reversal of rivaroxaban (250 ng/mL) inhibition assessed by the TF‐TG profiles compared to …